News

Inverna Therapeutics announces the formation of its Scientific Advisory Board consisting of world-renowned leaders in RNA therapeutics and neurodegenerative research

Inverna Therapeutics announces the formation of its Scientific Advisory Board consisting of world-renowned leaders in RNA therapeutics and neurodegenerative research

October 29, 2025

The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.

Read more

Inverna Therapeutics awarded grant from the Michael J. Fox Foundation for Parkinson’s research

Inverna Therapeutics awarded grant from the Michael J. Fox Foundation for Parkinson’s research

October 9, 2025

The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.

Read more

Inverna Therapeutics will participate in BIO-Europe 2025

Inverna Therapeutics will participate in BIO-Europe 2025

October 5, 2025

We are excited to participate in BIO-Europe 2025 and are looking forward to connect!

Read more

Inverna Therapeutics to showcase its groundbreaking RNA therapeutics platform at Nordic Life Science Days 2025

Inverna Therapeutics to showcase its groundbreaking RNA therapeutics platform at Nordic Life Science Days 2025

September 22, 2025

We are excited to participate in the NLSDays and honored to be selected as a finalist for the Nordic Star Pitch Competition.

Read more

Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark

Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark

January 7, 2025

The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.

Read more